When looking for the best stocks to buy and watch, focus on those with rising relative price strength.
One stock that fits that bill is Relay Therapeutics stock, which saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 84 to 94.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. IBD's proprietary RS Rating measures technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research shows that the market's biggest winners typically have an 80 or higher RS Rating as they begin their largest runs.
See How IBD Helps You Make More Money In Stocks
Is Relay Therapeutics Stock A Buy?
Relay Therapeutics stock recently retook its 200-day moving average and is not currently near a potential buy zone. See if the stock goes on to build a chart pattern that could ignite a new run. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The biotech company showed -10% EPS growth last quarter. Sales increased -56%.
Relay Therapeutics stock earns the No. 152 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharma, Genmab and Vertex Pharmaceuticals are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
